GlassScriptPhysician profile
Lisa M Parrillo
NPI 1659663482
$3,442.89
in general payments reported to CMS, 2019-2025
23 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $108 · 2021: $338 · 2022: $605 · 2023: $265 · 2024: $497 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440 · Travel and Lodging: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.61 |
| Travel and Lodging | $544.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,907.96 | 2021-2025 | Interstim, Altaviva |
| Medtronic USA, INC. | $326.52 | 2019-2020 | |
| Abbvie INC. | $281.80 | 2019-2025 | |
| Astellas Pharma US INC | $137.58 | 2022-2025 | Myrbetriq, Veozah, Xtandi |
| Merck Sharp & Dohme LLC | $134.83 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Allergan, INC. | $132.71 | 2019 | |
| Baxter Healthcare | $100.88 | 2024 | Tisseel |
| Urogen Pharma, INC. | $84.53 | 2022-2024 | Jelmyto |
| Laborie Medical Technologies Corp. | $73.75 | 2022 | |
| Olympus America INC. | $47.40 | 2025 | Itind System |
| Bluewind Medical | $39.31 | 2025 | Revi |
| Dendreon Pharmaceuticals LLC | $36.55 | 2023 | Provenge |
| Astrazeneca Pharmaceuticals LP | $30.44 | 2022-2025 | Lynparza |
| Janssen Biotech, INC. | $21.11 | 2025 | Erleada |
| Neotract INC. | $20.01 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $16.19 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.50 | 2025 | |
| Boston Scientific Corporation | $14.17 | 2021 | |
| Endo USA, INC. | $14.01 | 2024 | Xiaflex |
| Travere Therapeutics, INC. | $7.64 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$842,553.54 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Parrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.